Cargando…

Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control

OBJECTIVE: To study heterogeneity between patients with glycogen storage disease type Ia (GSD Ia), a rare inherited disorder of carbohydrate metabolism caused by the deficiency of glucose-6-phosphatase (G6Pase). STUDY DESIGN: Descriptive retrospective study of longitudinal clinical and biochemical d...

Descripción completa

Detalles Bibliográficos
Autores principales: Peeks, Fabian, Steunenberg, Thomas A. H., de Boer, Foekje, Rubio-Gozalbo, M. Estela, Williams, Monique, Burghard, Rob, Rajas, Fabienne, Oosterveer, Maaike H., Weinstein, David A., Derks, Terry G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579135/
https://www.ncbi.nlm.nih.gov/pubmed/28397058
http://dx.doi.org/10.1007/s10545-017-0039-1
_version_ 1783260647965851648
author Peeks, Fabian
Steunenberg, Thomas A. H.
de Boer, Foekje
Rubio-Gozalbo, M. Estela
Williams, Monique
Burghard, Rob
Rajas, Fabienne
Oosterveer, Maaike H.
Weinstein, David A.
Derks, Terry G. J.
author_facet Peeks, Fabian
Steunenberg, Thomas A. H.
de Boer, Foekje
Rubio-Gozalbo, M. Estela
Williams, Monique
Burghard, Rob
Rajas, Fabienne
Oosterveer, Maaike H.
Weinstein, David A.
Derks, Terry G. J.
author_sort Peeks, Fabian
collection PubMed
description OBJECTIVE: To study heterogeneity between patients with glycogen storage disease type Ia (GSD Ia), a rare inherited disorder of carbohydrate metabolism caused by the deficiency of glucose-6-phosphatase (G6Pase). STUDY DESIGN: Descriptive retrospective study of longitudinal clinical and biochemical data and long-term complications in 20 GSD Ia patients. We included 11 patients with homozygous G6PC mutations and siblings from four families carrying identical G6PC genotypes. To display subtle variations for repeated triglyceride measurements with respect to time for individual patients, CUSUM-analysis graphs were constructed. RESULTS: Patients with different homozygous G6PC mutations showed important differences in height, BMI, and biochemical parameters (i.e., lactate, uric acid, triglyceride, and cholesterol concentrations). Furthermore, CUSUM-analysis predicts and displays subtle changes in longitudinal blood triglyceride concentrations. Siblings in families also displayed important differences in biochemical parameters (i.e., lactate, uric acid, triglycerides, and cholesterol concentrations) and long-term complications (i.e., liver adenomas, nephropathy, and osteopenia/osteoporosis). CONCLUSIONS: Differences between GSD Ia patients reflect large clinical and biochemical heterogeneity. Heterogeneity between GSD Ia patients with homozygous G6PC mutations indicate an important role of the G6PC genotype/mutations. Differences between affected siblings suggest an additional role (genetic and/or environmental) of modifying factors defining the GSD Ia phenotype. CUSUM-analysis can facilitate single-patient monitoring of metabolic control and future application of this method may improve precision medicine for patients both with GSD and remaining inherited metabolic diseases.
format Online
Article
Text
id pubmed-5579135
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-55791352017-09-18 Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control Peeks, Fabian Steunenberg, Thomas A. H. de Boer, Foekje Rubio-Gozalbo, M. Estela Williams, Monique Burghard, Rob Rajas, Fabienne Oosterveer, Maaike H. Weinstein, David A. Derks, Terry G. J. J Inherit Metab Dis Original Article OBJECTIVE: To study heterogeneity between patients with glycogen storage disease type Ia (GSD Ia), a rare inherited disorder of carbohydrate metabolism caused by the deficiency of glucose-6-phosphatase (G6Pase). STUDY DESIGN: Descriptive retrospective study of longitudinal clinical and biochemical data and long-term complications in 20 GSD Ia patients. We included 11 patients with homozygous G6PC mutations and siblings from four families carrying identical G6PC genotypes. To display subtle variations for repeated triglyceride measurements with respect to time for individual patients, CUSUM-analysis graphs were constructed. RESULTS: Patients with different homozygous G6PC mutations showed important differences in height, BMI, and biochemical parameters (i.e., lactate, uric acid, triglyceride, and cholesterol concentrations). Furthermore, CUSUM-analysis predicts and displays subtle changes in longitudinal blood triglyceride concentrations. Siblings in families also displayed important differences in biochemical parameters (i.e., lactate, uric acid, triglycerides, and cholesterol concentrations) and long-term complications (i.e., liver adenomas, nephropathy, and osteopenia/osteoporosis). CONCLUSIONS: Differences between GSD Ia patients reflect large clinical and biochemical heterogeneity. Heterogeneity between GSD Ia patients with homozygous G6PC mutations indicate an important role of the G6PC genotype/mutations. Differences between affected siblings suggest an additional role (genetic and/or environmental) of modifying factors defining the GSD Ia phenotype. CUSUM-analysis can facilitate single-patient monitoring of metabolic control and future application of this method may improve precision medicine for patients both with GSD and remaining inherited metabolic diseases. Springer Netherlands 2017-04-10 2017 /pmc/articles/PMC5579135/ /pubmed/28397058 http://dx.doi.org/10.1007/s10545-017-0039-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Peeks, Fabian
Steunenberg, Thomas A. H.
de Boer, Foekje
Rubio-Gozalbo, M. Estela
Williams, Monique
Burghard, Rob
Rajas, Fabienne
Oosterveer, Maaike H.
Weinstein, David A.
Derks, Terry G. J.
Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
title Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
title_full Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
title_fullStr Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
title_full_unstemmed Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
title_short Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
title_sort clinical and biochemical heterogeneity between patients with glycogen storage disease type ia: the added value of cusum for metabolic control
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579135/
https://www.ncbi.nlm.nih.gov/pubmed/28397058
http://dx.doi.org/10.1007/s10545-017-0039-1
work_keys_str_mv AT peeksfabian clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT steunenbergthomasah clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT deboerfoekje clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT rubiogozalbomestela clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT williamsmonique clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT burghardrob clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT rajasfabienne clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT oosterveermaaikeh clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT weinsteindavida clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol
AT derksterrygj clinicalandbiochemicalheterogeneitybetweenpatientswithglycogenstoragediseasetypeiatheaddedvalueofcusumformetaboliccontrol